NBS NeoStem (NYSE MKT: NBS) Positive Results of A

NBS >>> NeoStem (NYSE MKT: NBS) Positive Results of AMR-001 for Treatment of AMI
Wed 3:51 pm by Henry McCusker
New Publication That Supports Positive Results



NBS’ new article published by the International Scholarly Research Network provides … further evidence that AMR-001 appears capable of preserving heart muscle function following a large myocardial infarction.

Amorcyte demonstrated in its P1 trial that AMR-001 preserved heart muscle function when a therapeutic dose of cells was administered. No patient experienced deterioration in heart muscle function who received 10 million cells or more whereas 30 to 40 percent of patients not receiving a therapeutic dose did.

The article titled “Assessment of myocardial contractile function using global and segmental circumferential strain following intracoronary stem cell infusion after myocardial infarction: MRI Feature Tracking Feasibility Study” by Sabha Bhatti, MD, et al. appears in ISRN Radiology Volume 2013, Article ID371028 and is published online at http://www.isrn.com/journals/radiology/2013/371028.



The Bottom Line: The new study shows that cardiac muscle function sparing effects are evident even earlier after treatment than previously shown. AMR-001 improved blood flow to the heart and preserved heart muscle. By using cardiac magnetic resonance imaging, specifically measuring circumferential strain of the left ventricle, the authors show that AMR-001?s effects are evident by 3 months after STEMI.AMR-001?s angiogenic and anti-apoptotic mechanisms of action indicate that preservation of heart muscle function should start within weeks and be evident in fewer than 6 months. This publication, based on blinded analysis of Amorcyte’s P1 data, confirms the expected time course for AMR-001?s mechanism of action.